" I think it's a terrific system, but I also can see a lot of problems with it," Shulman says. "When I started I was hoping we'd move towards 100 percent--now I think it has to be a mixture."
He is concerned that students may not receive as much information through the different curriculum as they would with a more traditional lecture format.
"Some students are nervous that they aren't getting enough material," Shulman says. "You have to rely a lot more on your classmates."
Financial concerns--small group courses require more faculty than a lecture-based curriculum--also hamper some schools from following HMS.
Federman says that HMS is "lucky in having such a large faculty and an extraordinary commitment to teaching."
Also, according to Schulman, students are used to traditional learning methods and may not take to change so easily. For this reason among others, he says Emory is not ready to make the switch yet.
"We feel pretty good about the graduates we turn out," Schulman says. "For us to make changes, we want to make sure that the changes will have substantial value."
Read more in News
War Means War in KosovoRecommended Articles
-
Dean Brings Human Touch to ScienceFor Dr. Daniel Federman '49, it's all about interpersonal relations. A charismatic smile and firm handshake greet all who enter
-
Exxon Grants Med School $500,000The Harvard Medical School(HMS) announced this week that the Exxon Foundation has granted $500,000 over the next three years to
-
Med School Class of '99: A Closer LookFifty years ago, Harvard Medical School (HMS) admitted its first two women candidates for the degree of doctor of medicine.
-
Future Physicians Learn How to LearnEditor's Note: This is the first in a two-part series examining the New Pathway curriculum at Harvard Medical School. In
-
In the Limelight: Students in `New Pathway'Editor's Note: This is the second of a two-part series on the New Pathway curriculum at Harvard Medical School. Luanda
-
HMS Report: Study Subjects Need ProtectionResearchers need to better protect patients in clinical trials and tighten oversight of medical studies, a national advisory panel headed
